These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36680930)

  • 81. Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer?
    Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett JMS; Xu B; Downes MR
    Pathol Res Pract; 2020 Nov; 216(11):153200. PubMed ID: 33022560
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
    Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
    J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
    Wang T; Niu X; Zhong B
    Jpn J Clin Oncol; 2022 May; 52(6):642-649. PubMed ID: 35348732
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
    Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
    Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.
    Massari F; Bria E; Ciccarese C; Munari E; Modena A; Zambonin V; Sperduti I; Artibani W; Cheng L; Martignoni G; Tortora G; Brunelli M
    PLoS One; 2015; 10(6):e0127908. PubMed ID: 26046361
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
    Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
    Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.
    Muilwijk T; Akand M; Daelemans S; Marien K; Waumans Y; Kockx M; Baekelandt L; Van den Broeck T; Van der Aa F; Gevaert T; Joniau S
    PLoS One; 2021; 16(9):e0257195. PubMed ID: 34525114
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Spachmann PJ; Azzolina V; Weber F; Evert M; Eckstein M; Denzinger S; Burger M; Otto W; Breyer J
    Pathol Oncol Res; 2020 Jul; 26(3):1625-1632. PubMed ID: 31506803
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Morphological and immunohistochemical characteristics of the molecular subtypes of urothelial carcinomas].
    Osmanov YI; Gaibov ZA; Kogan EA; Radenska-Lopovok SG; Tursunov KZ
    Arkh Patol; 2019; 81(5):35-44. PubMed ID: 31626203
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.
    Sjödahl G; Lövgren K; Lauss M; Chebil G; Patschan O; Gudjonsson S; Månsson W; Fernö M; Leandersson K; Lindgren D; Liedberg F; Höglund M
    Urol Oncol; 2014 Aug; 32(6):791-7. PubMed ID: 24794251
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer.
    Jackson CL; Chen L; Hardy CS; Ren KY; Visram K; Bratti VF; Johnstone J; Sjödahl G; Siemens DR; Gooding RJ; Berman DM
    J Pathol Clin Res; 2022 Mar; 8(2):143-154. PubMed ID: 34697907
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
    Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
    J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.
    Erdemir F; Ozcan F; Kilicaslan I; Parlaktas BS; Uluocak N; Gokce O
    Int Urol Nephrol; 2007; 39(4):1031-7. PubMed ID: 17340210
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.
    Shigeta K; Matsumoto K; Tanaka N; Mikami S; Kosaka T; Yasumizu Y; Takeda T; Mizuno R; Kikuchi E; Oya M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563543
    [TBL] [Abstract][Full Text] [Related]  

  • 95. GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder.
    Plage H; Samtleben H; Hofbauer S; Kornienko K; Weinberger S; Bruch PG; Elezkurtaj S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Klatte T; Schlomm T; Horst D; Zecha H
    Hum Pathol; 2022 Dec; 130():10-17. PubMed ID: 36152841
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [The expression of GGCT in the bladder urothelial cell carcinoma and its clinical significance].
    Guo YS; Wu YD; Ma H; Qi L; Zhang SD; Zang YJ
    Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1183-1187. PubMed ID: 34794221
    [No Abstract]   [Full Text] [Related]  

  • 97. Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16.
    Terlević R; Ulamec M; Štimac G; Murgić J; Krušlin B
    Biomol Biomed; 2023 Nov; 23(6):968-975. PubMed ID: 37389960
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases.
    Sjödahl G; Eriksson P; Lövgren K; Marzouka NA; Bernardo C; Nordentoft I; Dyrskjøt L; Liedberg F; Höglund M
    Mod Pathol; 2018 Dec; 31(12):1869-1881. PubMed ID: 29967424
    [TBL] [Abstract][Full Text] [Related]  

  • 99. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer.
    Ayari C; LaRue H; Hovington H; Caron A; Bergeron A; Têtu B; Fradet V; Fradet Y
    Hum Pathol; 2013 Aug; 44(8):1630-7. PubMed ID: 23574787
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.